Microfluidics Market is expected to reach US$ 73.97 billion by 2032

(EMAILWIRE.COM, March 21, 2025 ) Global Microfluidics Market reached US$ 28.38 billion in 2024 and is expected to reach US$ 73.97 billion by 2032, growing at a CAGR of 12.6 % during the forecast period 2025-2032.

Download Free Sample: https://www.datamintelligence.com/download-sample/microfluidics-market

Market Dynamics
Rising Demand for Point-of-Care Testing (POCT) Fuels Microfluidics Market Growth
The growing demand for point-of-care testing (POCT) is a key driver of the global microfluidics market and is expected to propel its expansion throughout the forecast period.

POCT plays a crucial role in modern healthcare by providing rapid diagnostic results directly at the site of patient care. This is particularly beneficial in emergency settings and remote healthcare facilities where access to traditional laboratories is limited. Microfluidic devices are at the heart of this advancement, enabling precise and efficient testing with minimal sample volumes essential for timely diagnosis and treatment.

With healthcare systems increasingly focused on efficiency and cost reduction, the adoption of POCT has surged. Microfluidics technology facilitates rapid diagnostics beyond conventional laboratory settings, significantly improving patient care and operational efficiency.
Moreover, ongoing research, industry partnerships, and technological innovations continue to drive market growth.

According to PIB News (August 2024), researchers have developed a droplet microfluidics technology that enables the production of microspheres with a high electroactive (EA) phase. This breakthrough enhances the development of cost-effective piezoelectric devices, paving the way for advanced self-powered sensors capable of monitoring various physiological signals an important step toward next-generation wearable healthcare technology.

Market Segments
• By Material Type (Silicon-Based Microfluidic, Glass-Based Microfluidic, Polymer-based microfluidic, Others)
• By Component (Microfluidic Chips, Micro Pumps, Microneedles, Others)
• By Application (In-vitro Diagnostics, Drug Delivery Devices, Monitoring Devices, Others)
• By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Read Our Report: https://www.datamintelligence.com/research-report/microfluidics-market

Market Regional Share
North America’s Dominance in the Global Microfluidics Market
North America holds a significant share of the global microfluidics market and is expected to maintain its leadership position throughout the forecast period.

The rising prevalence of chronic diseases, including diabetes, cancer, and cardiovascular conditions, is a key driver of market growth in the region. The demand for innovative diagnostic solutions has surged, with microfluidics playing a critical role in enabling rapid testing and personalized treatment strategies.

A well-developed healthcare infrastructure further strengthens North America’s position in the market. The region’s advanced medical ecosystem supports the widespread adoption of microfluidic technologies, particularly in diagnostics and drug delivery applications.

Additionally, the presence of leading industry players, strong government initiatives, regulatory support, and continuous technological advancements contribute to market expansion. For instance, in May 2024, Takara Bio USA, Inc. launched the Lenti-X Transduction Sponge, the first dissolvable microfluidic transduction enhancer. This groundbreaking product streamlines lentivirus-mediated gene delivery, marking a significant innovation in the field.

These factors collectively reinforce North America’s dominance in the global microfluidics market, driving continuous advancements and adoption across healthcare applications.

Key Market Players
Key players are Thermo Fisher Scientific Inc., PerkinElmer, Agilent Technologies, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Standard BioTools (Fluidigm Corporation), Merck KGaA, Sphere Fluidics., uFluidix, and Emulate Inc.

Recent Developments
In November 2024, LumiraDx introduced a Rapid Microfluidic Immunoassay C-Reactive Protein (CRP) Test aimed at addressing antimicrobial resistance (AMR) in India. This innovative test is designed to provide quick and accurate results, enabling healthcare providers to make informed decisions regarding the use of antibiotics.